Biology subjects

Hahn, M. K.

Publications and source records attributed to Hahn, M. K..

4 recordsLinked to original sources

bioRxiv2025

The fecal microbiota transplantation from drug-naive schizophrenia patients distinctively changes gut microbiome and metabolic profiles in male and female mice

BackgroundEmerging evidence suggests a role for the gut microbiome in schizophrenia (SCZ) and antipsychotic-induced metabolic perturbations. Using human fecal microbiota transplantation (FMT) in mice, this study investigated the role of gut microbiome in metabolic changes related to SCZ and antipsychotic (olanzapine) treatment. Methods5-6 weeks old germ-free NIH Swiss mice of both sexes received microbiota from either SCZ patients (SCZ-FMT) or healthy controls (HC-FMT) followed by a diet with or without olanzapine for six-weeks. Food intake and body weight were monitored weekly, and an intraperitoneal glucose tolerance test and open field test were performed. Serum glucose, and insulin were measured. Gut microbiome characterization and short-chain fatty acids (SCFAs) quantification were performed in the cecal samples using 16S rRNA gene sequencing and gas chromatography-mass spectrometry, respectively. ResultsOlanzapine treatment decreased the locomotor activity in the open field test, irrespective of sex or microbiota. Female SCZ-FMT recipient mice exhibited insulin resistance compared to HC-FMT, irrespective of olanzapine treatment. Female SCZ-FMT mice showed significantly lower alpha-diversity compared to HC-FMT, whereas olanzapine treatment increased alpha-diversity. SCZ-FMT and olanzapine treatment differentially altered the microbial abundances, and metabolic pathways in male and female mice. Interestingly, cecal SCFAs, mainly acetate levels, were significantly decreased in female SCZ-FMT mice compared to HC-FMT, while olanzapine treatment increased acetate levels in male mice. Both male and female SCZ-FMT mice showed elevated levels of isovaleric acid compared to HC-FMT. ConclusionThese preliminary findings suggest that gut microbiome could be a predisposing factor contributing to the intrinsic risk of developing type 2 diabetes associated with SCZ in females. O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=80 SRC="FIGDIR/small/675957v1_ufig1.gif" ALT="Figure 1"> View larger version (31K): org.highwire.dtl.DTLVardef@8cfd10org.highwire.dtl.DTLVardef@3a6031org.highwire.dtl.DTLVardef@813428org.highwire.dtl.DTLVardef@87609e_HPS_FORMAT_FIGEXP M_FIG Graphical abstract C_FIG

neuroscience↗

bioRxiv2025

Protective effects of central leptin on whole-body energy homeostasis upon acute olanzapine exposure

Second-generation antipsychotic use is associated with severe metabolic side effects such as obesity and type 2 diabetes. Leptin is a hormone that is secreted by adipose tissue, and it acts on the brain to decrease body weight by reducing food intake and stimulating energy expenditure. Leptin also improves glucose and lipid metabolism. We examined the short-term impact of olanzapine, a commonly used second-generation antipsychotic, on the central leptin-mediated regulation of energy balance, lipid metabolism, and hypothalamic kinase activity. Male Sprague Dawley rats were given an acute intracerebroventricular (ICV, 3rd ventricle) injection of either leptin or vehicle, combined with subcutaneous olanzapine or vehicle. As expected, ICV leptin decreased food intake and importantly, olanzapine did not block this effect. Administration of leptin, olanzapine, or their combination reduced the average respiratory exchange ratio (RER) during the light cycle, which indicates that fat oxidation was increased. In the dark cycle, leptin decreased the average RER regardless of olanzapine administration, and in the presence of leptin, olanzapine did not affect the average RER. Leptin did not alter the olanzapine-induced increase in serum triglyceride concentrations. Olanzapine and central leptin treatment differentially activated hypothalamic kinases. In conclusion, regulation of food intake and fuel preference by central leptin is intact following acute olanzapine administration.

neuroscience↗

bioRxiv2024

Development of novel tools for dissection of central versus peripheral dopamine D2-like receptor signaling in dysglycemia

Dopamine (DA) D2-like receptors in both the central nervous system (CNS) and the periphery are key modulators of metabolism. Moreover, disruption of D2-like receptor signaling is implicated in dysglycemia. Yet, the respective metabolic contributions of CNS versus peripheral D2-like receptors including D2 (D2R) and D3 (D3R) receptors remain poorly understood. To address this, we developed new pharmacological tools, D2-like receptor agonists with diminished and delayed blood-brain barrier capability, to selectively manipulate D2R/D3R signaling in the periphery. We designated bromocriptine methiodide (BrMeI), a quaternary methiodide analogue of D2/3R agonist and diabetes drug bromocriptine, as our lead compound based on preservation of D2R/D3R binding and functional efficacy. We then used BrMeI and unmodified bromocriptine to dissect relative contributions of CNS versus peripheral D2R/D3R signaling in treating dysglycemia. Systemic administration of bromocriptine, with unrestricted access to CNS and peripheral targets, significantly improved both insulin sensitivity and glucose tolerance in obese, dysglycemic mice in vivo. In contrast, metabolic improvements were attenuated when access to bromocriptine was restricted either to the CNS through intracerebroventricular administration or delayed access to the CNS via BrMeI. Our findings demonstrate that the coordinated actions of both CNS and peripheral D2-like receptors are required for correcting dysglycemia. Ultimately, the development of a first-generation of drugs designed to selectively target the periphery provides a blueprint for dissecting mechanisms of central versus peripheral DA signaling and paves the way for novel strategies to treat dysglycemia.

neuroscience↗

bioRxiv2021

Sex and Circuit Specific Dopamine Transporter Regulation Underlies Unique Behavioral Trajectories of Functional SLC6A3 Coding Variation

Virtually all neuropsychiatric disorders display sex differences in prevalence, age of onset, and/or clinical symptomology. In sex-biased disorders, one sex is often suggested to harbor protective mechanisms, rendering them resilient to genetic and/or environmental risk factors. Here, we demonstrate sex-biased molecular, pharmacological and behavioral effects induced by the dopamine (DA) transporter (DAT) coding variant Ala559Val, previously identified in subjects diagnosed with the male-biased disorders attention-deficit/hyperactivity disorder and autism spectrum spectrum disorder. In DAT Val559 mice, we identified sex differences in response to psychostimulants, social behavior, and cognitive traits. We reveal a sex by circuit dissociation in D2-type autoreceptor (D2AR) regulation of DAT wherein D2AR-dependent DAT phosphorylation and trafficking, detectable in the male dorsal striatum, does not occur in females but rather is a property of the ventral striatum, predicting sex-specific changes in behavior. Consequently, we found that a subset of altered behaviors can be normalized using the D2R antagonist sulpiride in DAT Val559 mice. Our studies provide a cogent example of how sex shapes the behavioral trajectory of DA signaling perturbations and identify the sex-dependent, locality-selective capacity for D2AR regulation of DAT as an unrecognized determinant of this trajectory. Rather than identifying one sex as resilient, we find that sex can drive alterative behavioral patterns from shared signaling perturbations that may result in females being underreported. Our work underscores the utility of model systems to study the functional intrusions of rare genetic variation to gain insights into pathways underlying normal and perturbed trait domains associated with common neuropsychiatric conditions.

neuroscience↗